By FSD Pharma on Friday, 04 October 2019
Category: Vertically Integrated

Buds & Duds: Cannabis stocks remain mostly flat heading into the weekend; Canopy Growth falls after Constellation Brands writedown

Litelink Technologies moved higher on Friday after signing a new agreement to track cannabis plantlets

Also on the move was FSD Pharma, Kalytera Therapeutics and MedMen Enterprises

Cannabis investors let out a sigh of relief on Friday as shares remained flat across North America heading into the weekend.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was in the green to start the morning but dropped slightly, down 0.9% to 152.4 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF inched 0.5% higher to C$12.18, while the OTCQX Cannabis Index was up 0.6% to 552.6 points.

Buds

Most pot companies were quiet on Friday but a few managed to stand out from the pack.

Inc () (OTCMKTS:FSDDF) shares were up on Friday morning following the announcement earlier in the week that it has extended its previously announced private placement of class B subordinate voting shares in to a second tranche.

The move was to accommodate potential additional interest from institutional grade investors, having closed a first tranche on September 30, the Toronto-based cannabis company told investors.

Shares of FSD grew 7.1% to reach C$0.08 in Canada and 5% on OTC markets to hit US$0.06.

Litelink Technologies Inc () (OTCMKTS:LLNKF), the Canadian logistics and digital tracking company, revealed Friday that it had entered into an agreement with cannabis agriculture technology firm Segra International to track the latter’s plantlets.

LiteLink will use its flagship 1SHIFT Logistics software so Segra knows exactly where the plantlets are at any time and provide real-time and historical temperature readouts, as well as total travel time logs.

Shares of Litelink rose 5.7% in Canada at C$0.19 and 6.1% on OTC markets at US$0.14.

(CVE:KLY) () also made gains in Canada on Friday, with its shares rising 14.3% at C$0.04 following the announcement earlier this week that it had received a European patent covering the use of CBD in the treatment of graft versus host disease.

Duds

() (NYSE:CGC) lost ground on Friday after Inc () revealed in its second quarter results that it had taken an US$839 million write-down in the value of its earlier investment in the pot behemoth.

Shares of Canopy Growth fell 2% in Toronto to C$30.50 and 1.5% in New York to hit US$23.03 on Friday morning.

Constellation’s shares, which lost 5% in New York on Thursday, stayed relatively flat on Friday morning at US$194.55.

Other companies in the red on Friday included () (OTCMKTS:MMNFF), down 7.5% in Canada at C$$2.22 and 6.7% on OTC markets at US$1.67.

CV Sciences Inc () also took a 7.4% hit to its share price, trading at US$2.39.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Related Posts